Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Debt / NOTE 4.500% 7/1
-
Number of holders
-
8
-
Total 13F principal, excl. options
-
52,609,000
-
Principal change
-
+5,000
-
Total reported value, excl. options
-
$49,876,000
-
Value change
-
-$2,913,950
-
Number of buys
-
3
-
Number of sells
-
-7
-
Price
-
$0.9410
Significant Holders of MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 as of Q4 2016
11 filings reported holding 590328AA8 - MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 as of Q4 2016.
MERRIMACK PHARMACEUTICALS IN - NOTE 4.500% 7/1 has 8 institutional bondholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of $52,609,000 of principal
.
Largest 10 bondholders include HIGHBRIDGE CAPITAL MANAGEMENT LLC ($23,262,000 of principal), WOLVERINE ASSET MANAGEMENT LLC ($12,698,000 of principal), LAZARD ASSET MANAGEMENT LLC ($6,300,000 of principal), AMERIPRISE FINANCIAL INC ($3,320,000 of principal), PUTNAM INVESTMENTS LLC ($2,876,000 of principal), JPMORGAN CHASE & CO ($2,815,000 of principal), PALISADE CAPITAL MANAGEMENT LLC/NJ ($1,331,000 of principal), WELLS FARGO & COMPANY/MN ($7,000 of principal), Polygon Management Ltd. ($0 of principal), and Polar Capital LLP ($0 of principal).
This table shows the top 8 institutional bondholders of the company debt. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.